Le Lézard
Classified in: Health
Subjects: NPT, POL

AARP Pushes Back on PhRMA's Attempts to Change Medicare Part D Doughnut Hole Deal


WASHINGTON, Sept. 21, 2018 /PRNewswire/ -- AARP Executive Vice President and Chief Advocacy & Engagement Officer Nancy LeaMond released the following statement in response to lobbying efforts by PhRMA to change the Medicare Part D doughnut hole deal:  

AARP national logo. (PRNewsfoto/AARP)

"AARP strongly opposes PhRMA's attempts to cut a backroom deal with Congress and reverse the Medicare Part D doughnut hole improvements enacted earlier this year that put drugmakers on the hook for a higher share of Medicare drug costs.

"The Part D doughnut hole improvements, which are now law, are good for seniors. These improvements will save seniors billions of dollars in out-of-pocket costs on their prescription medications by moving them through the prescription drug coverage gap faster, which results in lower co-payments. 

"At a time when seniors are struggling to afford high drug prices, we need to be doing more, not less, to help lower their drug costs and we certainly should not roll back the progress that has been made.

"On behalf of our 38 million members, we strongly urge Congress to stand up to PhRMA and reject any attempts to reverse the Part D doughnut hole deal. Any change to the current law will simply be a windfall for the pharmaceutical industry that will only raise seniors' drug costs."

About AARP
AARP is the nation's largest nonprofit, nonpartisan organization dedicated to empowering people 50 and older to choose how they live as they age. With a nationwide presence and nearly 38 million members, AARP strengthens communities and advocates for what matters most to families: health security, financial stability and personal fulfillment. AARP also produces the nation's largest circulation publications: AARP The Magazine and AARP Bulletin. To learn more, visit www.aarp.org or follow @AARP and @AARPadvocates on social media.

 

SOURCE AARP


These press releases may also interest you

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: